Back to search results

Understanding MK-2828 in People with Kidney Disease

This study is looking at how the drug MK-2828 moves through the body of people with kidney disease, including chronic kidney failure and end-stage renal disease. Researchers want to see if this process is similar to what happens in healthy people. We are measuring how much MK-2828 is in your blood over time after taking one or two doses. This helps us understand how the drug is absorbed, distributed, and removed from the body. The study is open to adults aged 24 to 85 years old who are generally in good health, apart from their kidney condition. The goal is to compare how MK-2828 behaves in people with different levels of kidney function.

Study design
This is an interventional study with a planned enrollment of 24 participants. It aims to understand how MK-2828 is processed by the body.
What's involved
You would take one or two doses of MK-2828. Blood samples will be taken before and at various times up to 192 hours (8 days) after your dose.
Compensation
Not stated in the trial record.
Follow-up
Your blood levels of MK-2828 will be measured for up to 192 hours (8 days) after your dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07348237

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

Recruiting
PHASE1Ages 24–85InterventionalTreatment
Merck Sharp & Dohme LLC
~24 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:MK-2828

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of MK-2828 in Plasma
Measured over Pre dose and at designated time points up to 192 hours post dose
+8 more outcomes measured

Conditions

Chronic Kidney Failure
End-Stage Renal Disease
Renal Impairment

Explore related trials

Chronic Renal FailureRenal Impairment

Where it's being run

3 sites across 1 states
Florida3

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

Toll Free Number
[email protected]
1-888-577-8839
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Is in generally good health, with the exception of renal impairment participants. Participants with stable, chronic medical or psychiatric conditions may be included at the discretion of the investigator and the Sponsor.
Has an estimated glomerular filtration rate (eGFR) \< 30 mL/min), but is not on hemodialysis (HD)
Has ESRD maintained on stable outpatient regimen of intermittent high-flux HD at a healthcare center for \> 3 months prior to study entry

Exclusion

History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.

What this trial measures

  • Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of MK-2828 in PlasmaPre dose and at designated time points up to 192 hours post dose

    Blood samples will be collected to determine the AUC0-inf of MK-2828

  • Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of MK-2828 in PlasmaPre dose and at designated time points up to 192 hours post dose

    Blood samples will be collected to determine the AUC0-last of MK-2828

  • Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of MK-2828 in PlasmaPre dose and at designated time points up to 24 hours post dose

    Blood samples will be collected to determine the AUC0-24 of MK-2828

  • Maximum Plasma Concentration (Cmax) of MK-2828 in PlasmaPre dose and at designated time points up to 192 hours post dose

    Blood samples will be collected to determine the Cmax of MK-2828

  • Time of the Maximum Observed Concentration (Tmax) of MK-2828 in PlasmaPre dose and at designated time points up to 192 hours post dose

    Blood samples will be collected to determine the Tmax of MK-2828

  • Concentration at 24 Hours Postdose (C24) of MK-2828 in PlasmaAt designated time points up to 24 hours post dose

    Blood samples will be collected to determine the C24 of MK-2828

  • Apparent Terminal Elimination Half-life (t1/2) of MK-2828 in PlasmaPre dose and at designated time points up to 192 hours post dose

    Blood samples will be collected to determine the t1/2 of MK-2828

  • Apparent Total Plasma Clearance (CL/F) of MK-2828Pre dose and at designated time points up to 192 hours post dose

    Blood samples will be collected to determine the CL/F of MK-2828

  • Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of MK-2828 in PlasmaPre dose and at designated time points up to 192 hours post dose

    Blood samples will be collected to determine the Vz/F of MK-2828